ADMA: Long Term Revenue Outlook And Buybacks Will Support Future Upside

Analysts have trimmed their price targets on ADMA Biologics by roughly one third to about $18.33, citing updated assumptions around growth, profitability, and future P/E multiples following recent initiation, target cuts, and a downgrade.

Analyst Commentary

Recent Street research around ADMA Biologics reflects both optimism about the company’s setup and fresh caution around execution and valuation, which is feeding directly into the trimmed price targets.

Bullish Takeaways

Bullish analysts who recently initiated coverage describe ADMA as having an attractive story, enough to support initial ratings that pointed to upside from current levels before the later target reductions.
The initiation with a bullish view suggests confidence that the company has identifiable growth drivers that, if delivered, could make current valuation metrics look reasonable over time.
Supportive research implies that, despite recent cuts, some on the Street still see room for execution on the core business plan that could justify using higher P/E multiples than more challenged peers.
The combination of initiation and ongoing coverage indicates that ADMA remains firmly on the radar for analysts looking for healthcare stocks where operational progress could eventually support a higher equity value.

Bearish Takeaways

Bearish analysts have lowered price targets by US$3 and US$6 in recent reports, indicating reduced confidence around prior assumptions for growth, profitability, or appropriate P/E levels.
At least one downgrade tied to a short report highlights concern around information gaps or perceived risks that may not yet be fully reflected in consensus models.
The more cautious stance signals that some analysts now see less room for multiple expansion and are placing more weight on near term execution risk and visibility.
Overall, the mix of target cuts and a downgrade suggests the hurdle for ADMA to meet or exceed Street expectations on both growth and margins has risen, which can keep valuation more constrained until there is clearer evidence on delivery.

What's in the News

Short seller Culper Research published a report on ADMA Biologics, calling the company’s reported growth “a fiction,” which has added to the debate around its fundamentals and disclosures (periodical).
The U.S. Food and Drug Administration approved ADMA’s supplemental Biologics License Application for ASCENIV, expanding its primary humoral immunodeficiency indication to pediatric patients 2 years of age and older and updating the prescribing information (Key Development).
ADMA announced a Chief Financial Officer transition, with long time CFO Brad Tade set to retire in February 2026 and Terry Kohler appointed as the new CFO and Treasurer. Tade will remain as a consultant through July 2026 to support continuity (Key Development).
The company reiterated earnings guidance for 2026 and 2027, stating that it expects total revenue to exceed US$635m in 2026 and US$775m in 2027 (Key Development).
ADMA reported that between October 1 and December 31, 2025, it repurchased 590,422 shares for US$8.91m, completing a total buyback of 1,919,070 shares for US$31.92m under a previously announced program (Key Development).

Valuation Changes

Fair Value: Trimmed from $27.25 to about $18.33, a reduction of roughly one third in the central valuation estimate.
Discount Rate: Increased from 7.06% to about 7.27%, indicating a slightly higher required return being applied to future cash flows.
Revenue Growth: Adjusted from 24.38% to about 20.80%, reflecting more conservative top line assumptions in the updated model.
Net Profit Margin: Increased from 41.14% to about 42.45%, with analysts incorporating a modestly higher profitability level despite the lower revenue growth rate.
Future P/E: Reset from 20.67x to about 12.57x, indicating a meaningfully lower valuation multiple being used for ADMA Biologics in the forecast period.

30 views

Key Takeaways

Adoption of manufacturing improvements, capacity expansions, and new products is driving margin growth, revenue diversification, and improved supply chain resilience.
Enhanced liquidity from refinancing and strong market demand underpins strategic growth initiatives and positions the company for sustained earnings improvement.
Heavy dependence on a limited product line, manufacturing and supply chain risks, and strong competition threaten future growth, profitability, and market share in a shifting healthcare landscape.

Catalysts

About ADMA Biologics

A biopharmaceutical company, develops, manufactures, and markets specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally.What are the underlying business or industry changes driving this perspective?

Commercial-scale implementation of the FDA-approved yield enhancement process is producing a 20%+ increase in bulk immunoglobulin output, expected to drive sustained gross margin expansion and higher net income starting in early 2026 and beyond.
Rapidly increasing adoption and utilization of ASCENIV, with a growing number of physicians and patient starts, is supported by aging populations and rising prevalence of immunodeficiency and infectious diseases-secular trends likely to drive ADMA's top-line revenue growth for years to come.
Expansion of plasma collection volumes and the acquisition of new facilities are set to increase production capacity and supply chain resilience, positioning ADMA to capture greater market share and further accelerate revenue growth and earnings over the long term.
The recent debt refinancing, lowering the cost of capital and providing a new $300 million credit facility, enhances liquidity and financial flexibility, supporting ongoing strategic growth initiatives and potentially improving future free cash flow and EPS.
Continued progress in the product pipeline-including SG-001, which addresses unmet infectious disease needs and could potentially add $300–$500 million in annual revenue-offers significant future earnings upside and diversification of revenue streams.

ADMA Biologics Earnings and Revenue Growth

ADMA Biologics Future Earnings and Revenue Growth

Assumptions

How have these above catalysts been quantified?

Analysts are assuming ADMA Biologics's revenue will grow by 20.8% annually over the next 3 years.
Analysts assume that profit margins will increase from 32.4% today to 42.4% in 3 years time.
Analysts expect earnings to reach $381.5 million (and earnings per share of $1.58) by about May 2029, up from $165.4 million today. However, there is a considerable amount of disagreement amongst the analysts with the most bullish expecting $435.4 million in earnings, and the most bearish expecting $321.3 million.
In order for the above numbers to justify the price target of the analysts, the company would need to trade at a PE ratio of 12.6x on those 2029 earnings, up from 11.9x today. This future PE is lower than the current PE for the US Biotechs industry at 17.8x.
Analysts expect the number of shares outstanding to decline by 2.92% per year for the next 3 years.
To value all of this in today's terms, we will use a discount rate of 7.27%, as per the Simply Wall St company report.

Risks

What could happen that would invalidate this narrative?

ADMA's heavy reliance on a narrow product portfolio-primarily ASCENIV® and BIVIGAM®-leaves the company vulnerable to product-specific competition, potential regulatory setbacks, or clinical disappointments, which could materially impact future revenue growth and earnings stability.
The anticipated long-term margin expansion and revenue acceleration is highly dependent on the successful commercial scale-up and sustained efficiency of the proprietary yield enhancement manufacturing process; unforeseen scale-up challenges, regulatory delays, or operational disruptions at the Boca Raton facility could undermine projected cost reductions and gross margin improvements, resulting in weaker-than-expected profitability.
Persistent operating risks associated with plasma collection-such as potential supply constraints from donor fatigue, changes in donor demographics, or tighter industry regulations-may drive up raw material costs and disrupt supply chain continuity, posing a threat to cost of goods sold and net margin performance.
Increasing competition from larger, better-capitalized plasma industry leaders (e.g., CSL, Takeda, Grifols) with broader distribution networks and R&D resources may limit ADMA's ability to maintain high revenue growth rates and exert pricing power, potentially eroding future market share and constraining revenue expansion.
Secular healthcare trends-such as global cost containment, downward pressure on reimbursement rates, and advances in synthetic/alternative immunology therapies-could eventually reduce demand for plasma-derived products and compress pricing, negatively impacting long-term top-line growth and reducing the company's ability to sustain margin expansion.

Valuation

How have all the factors above been brought together to estimate a fair value?

The analysts have a consensus price target of $18.33 for ADMA Biologics based on their expectations of its future earnings growth, profit margins and other risk factors.
In order for you to agree with the analysts, you'd need to believe that by 2029, revenues will be $898.8 million, earnings will come to $381.5 million, and it would be trading on a PE ratio of 12.6x, assuming you use a discount rate of 7.3%.
Given the current share price of $8.47, the analyst price target of $18.33 is 53.8% higher.
We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.

Have other thoughts on ADMA Biologics?

Create your own narrative on this stock, and estimate its Fair Value using our Valuator tool.

Create Narrative

How well do narratives help inform your perspective?

Disclaimer

AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.

Share Repurchase And Higher Margins Will Drive Future Upside Potential